EUVIMEDEUVIMED entdecken
ÄquivalenzstudieBeobachtungsstudie

Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections

Esrat Jahan, Alex Matika, Lauren Allen, Justin Miller

Infection · 2026-10 · 54 (5) · 2663-2670

DOI: 10.1007/s15010-026-02898-5 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Infection, online erschienen am 27.08.2026. Verfasst von Esrat Jahan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, St. Luke's University Health Network, Bethlehem, PA, USA. esrat1205@gmail.com. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Enterococcus, Gram-Positive Bacterial Infections. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Growing evidence supports oral transition therapy for gram-negative and certain Staphylococcus bloodstream infections (BSIs). However, clinical data remains limited for other organisms. The purpose of this study is to assess whether oral transition therapy is non-inferior to intravenous (IV)-only therapy for uncomplicated Enterococcal BSIs. METHODS: This single-center, retrospective, non-inferiority, observational study included adult patients with microbiology-confirmed Enterococcus bacteremia who received appropriate definitive antibiotic therapy. The primary composite outcome was treatment failure, defined as recurrence of BSI, development of deep-seated infection, or all-cause mortality within 90 days. Secondary outcomes included the individual components of the composite outcome, readmission within 90 days related to the index infection, hospital length of stay, and treatment-emergent adverse events. RESULTS: Of the 156 included patients, 123 received IV-only therapy, and 33 were transitioned to oral therapy. Treatment failure occurred in 18% (22/123) of patients in the IV-only group and 12% (4/33) in the oral group (RR 0.68, 95% CI 0.25-1.83), with a similar safety profile observed in both groups. Additionally, the hospital length of stay was significantly shorter in the oral group (6 vs. 8 days, p < 0.01). CONCLUSION: Given this study was underpowered, a statistical non-inferiority could not be established. However, given a numerically lower rate of treatment failure observed in the oral therapy group without any overt safety concern, oral transition therapy may be considered in clinically stable patients with uncomplicated Enterococcal BSIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaEnterococcusGram-Positive Bacterial InfectionsAdultAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousAdministration, OralBridge TherapyRetrospective StudiesTreatment FailureTreatment Outcome

Stichwörter der Autor:innen

Enterococcal bacteremiaOral transitionTreatment failure

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, St. Luke's University Health Network, Bethlehem, PA, USA. esrat1205@gmail.com.
  • , 801 Ostrum St, Bethlehem, PA, 18015, USA. esrat1205@gmail.com.
  • Department of Pharmacy, St. Luke's University Health Network, Bethlehem, PA, USA.

Zitieren

APA

Jahan, E., Matika, A., Allen, L., & Miller, J. (2026). Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections. Infection, 54(5), 2663-2670. https://doi.org/10.1007/s15010-026-02898-5

Vancouver

Jahan E, Matika A, Allen L, Miller J. Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections. Infection. 2026;54(5):2663-2670. doi:10.1007/s15010-026-02898-5

BibTeX
@article{Jahan2026,
  author = {Jahan, Esrat and Matika, Alex and Allen, Lauren and Miller, Justin},
  title = {Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections},
  journal = {Infection},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {2663--2670},
  doi = {10.1007/s15010-026-02898-5}
}
Kostenlos starten →